Accro Bioscience Doses First Patient in Ulcerative Colitis Phase IIb Study

Accro Bioscience has initiated its Phase IIb clinical study to evaluate the efficacy and safety of its drug candidate, AC-101, in patients with moderate-to-severe ulcerative colitis. The company announced the first patient has been dosed in the study, which is being conducted in the United States and China.

The study aims to assess AC-101's impact on disease progression and patient symptoms. Ulcerative colitis is a chronic inflammatory bowel disease affecting millions globally. Current treatments are not always sufficiently effective or carry significant side effects, creating a need for novel therapeutic options.

Accro Bioscience focuses on developing AC-101 for immune-mediated diseases. The company previously completed Phase I and IIa studies that indicated preliminary safety and efficacy. The results from the Phase IIb study will be critical for the continued development of AC-101.

The company has not provided a specific timeline for the study's completion but anticipates the findings will clarify AC-101's potential as a treatment for ulcerative colitis.